ºÚÁÏÍø

Abstract

Objectives: As SARS-Cov-2 infection leads to the development of cytokine storm syndrome, Tocilizumab, a biological agent that inhibits the cytokine interleukin 6, was seen to have clinical effects in COVID-19. Hematological markers used to determine clinical severity based on current literature revealed that ALC, CRP, Ferritin, LDH and D-dimer levels were associated with COVID severity. We aimed to determine the association of recovery and mortality rate with Tocilizumab based on inflammatory markers significant in COVID-19 infection such as CRP, LDH, D-dimer, Ferritin, Absolute Lymphocyte Count and associate comorbidities of patients to mortality. Methods: This was a single-center retrospective study which includes 101 t patients diagnosed with COVID-19 Severe and Critical Pneumonia. Independent Sample T-test, Mann-Whitney U test and Fisher�s Exact/Chi-square test was used. Odds ratio was computed to determine significant predictors for mortality. Results: Diabetic patients were 5.3 times more likely to and Chronic Kidney Disease was 18 times more likely to have mortality. For every unit increase in patient�s D-dimer and CRP during admission, the odds of mortality also increase by 0.02% and 0.73%, 0.01, unit decrease in patient�s Absolute 0.02,w Lymphocyte Count during admission, the odds of Mortality decrease by 17.86%. Every 0.01-unit increase in patient�s ABG PaO2/FiO2 during admission, the odds of mortality decrease by 10.1%. In patient�s D-dimer, Ferritin, CRP and LDH prior to discharge, every unit increase, the odds of mortality also increase by 0.03%, 0.18%, 2.29% and 0.58, respectively. Every 0.01-unit increase in patient�s ALC prior discharge, mortality decrease by 13.35%. Conclusion: Tocilizumab treatment was associated with reduction in the mortality of patient with Severe and Critical COVID Pneumonia in association with inflammatory markers, LDH, Ferritin, D-dimer and CRP, improvement of ABG PaO2/FIO2 and decreased infiltrates by chest x-ray. Mortality from COVID-19 Pneumonia was associated with CKD, DMT2, and HCVD Recent Publications Manalo, G., Lu-Reyes, J., Carabbacan C., Santos, M., Pascual, S. Therapeutic Plasma Exchange as a Treatment for Central Pontine Myelinolysis in a 41 year old Male with Chronic Renal Insufficiency: A Case Report; Philippine Journal of Internal Medicine (Volume 60 No. 4)

Biography

Sheryll J.Pascual MD in Internal Medicine Physician at Mariano Marcos Memorial Hospital and Medical Center, Philippines. She finished her residency training in internal medicine last December 2022 and Currently Medical Officer on the said institution.